Abstract
Biglycan is a class I secreted small leucine-rich proteoglycan (SLRP) which regulates signaling pathways connected to bone pathologies. Autophagy is a vital catabolic process with a dual role in cancer progression. Here, we show that biglycan inhibits autophagy in two osteosarcoma cell lines (p ≤ 0.001), while rapamycin-induced autophagy decreases biglycan expression in MG63 osteosarcoma cells and abrogates the biglycan-induced cell growth increase (p ≤ 0.001). Rapamycin also inhibits β-catenin translocation to the nucleus, inhibiting the Wnt pathway (p ≤ 0.001) and reducing biglycan's colocalization with the Wnt co-receptor LRP6 (p ≤ 0.05). Furthermore, biglycan exhibits protective effects against the chemotherapeutic drug doxorubicin in MG63 OS cells through an autophagy-dependent manner (p ≤ 0.05). Co-treatment of these cells with rapamycin and doxorubicin enhances cells response to doxorubicin by decreasing biglycan (p ≤ 0.001) and β-catenin (p ≤ 0.05) expression. Biglycan deficiency leads to increased caspase-3 activation (p ≤ 0.05), suggesting increased apoptosis of biglycan-deficient cells treated with doxorubicin. Computational models of LRP6 and biglycan complexes suggest that biglycan changes the receptor's ability to interact with other signaling molecules by affecting the interdomain bending angles in the receptor structure. Biglycan binding to LRP6 activates the Wnt pathway and β-catenin nuclear translocation by disrupting β-catenin degradation complex (p ≤ 0.01 and p ≤ 0.05). Interestingly, this mechanism is not followed in moderately differentiated, biglycan non-expressing U-2OS OS cells. To sum up, biglycan exhibits protective effects against the doxorubicin in MG63 OS cells by activating the Wnt signaling pathway and inhibiting autophagy. .
Full text
